Kishore Iyer, MD
Transplant Surgery · New York, NYNPI 1447245303
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $89,484 of the $94,868 with a category attached, or 94.3%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 79.7% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $26,606, more than ten times the $1,228 reported in 2019. Among transplant surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 47 payments — averaging $2018.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$76K
- Vectivbio AG$14K
- Ipsen Bioscience Inc.$4K
- Baxter Healthcare$1K
- KCI USA, Inc.$118
- Ironwood Pharmaceuticals, Inc$80
- plus $17 from 1 others
Across 112 payments — averaging $1791.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vectivbio AG$129K
- Takeda Pharmaceuticals U.S.A., Inc.$43K
- Shire North American Group Inc$19K
- Zealand Pharma A/s$10K
What the payments were for
- Consulting fees$89,48494%
- Travel & lodging$4,4115%
- Food & beverage$9721%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $75,605 |
| Vectivbio AG | 4 | $14,280 |
| Ipsen Bioscience Inc. | 1 | $3,540 |
| Baxter Healthcare | 3 | $1,228 |
| KCI USA, Inc. | 1 | $118 |
| Ironwood Pharmaceuticals, Inc | 1 | $80 |
| Fresenius Kabi USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GATTEX$69,436
- IPS - Nutrition$1,120
- FISTULA SOLUTION$118
How this compares
$94,868 in reported general payments places this provider in the 95th percentile of 72 transplant surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CresembaIsavuconazonium Sulfate | 11 | $49,673 |
| Valganciclovir Hcl | 18 | $7,232 |
| Tacrolimus | 19 | $2,502 |
| LoperamideLoperamide Hcl | 23 | $1,467 |
| Sodium Chloride0.9 % Sodium Chloride | 36 | $886 |
| Sodium ChlorideSodium Chloride 0.45 % | 49 | $763 |
| Gentamicin Sulfate | 27 | $693 |
| Famotidine | 61 | $602 |
| Nystatin | 12 | $414 |
| Vancomycin Hcl | 17 | $208 |
| Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12) | 13 | $68 |
| Pantoprazole Sodium | 17 | $45 |
| Prednisone | 13 | $34 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $27 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius Kabi USA, LLCSodium Chloride, Sodium Chloride | $17 | $1,64985 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 72 transplant surgery providers in New York.
Other transplant surgery in New York
- Jason HawksworthNew York$91K
- Parissa TabrizianNew York$74K
- Lloyd RatnerNew York$32K
- Hautien LiouNew York$31K
- Karim HalazunNew York$28K
- Myron SchwartzNew York$27K
- Ron ShapiroNew York$16K
- Gabriel GondolesiNew York$15K
- Lewis TepermanNew York$13K
- Babak OrandiNew York$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.